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Sarcopenia is defined by decreased muscle mass and
impaired muscle function, which may be associated with
frailty and eventually higher mortality rates. It is physio-
logically induced by aging but also related to obesity by
different mechanisms such as 1) diminished physical
activity; 2) elevated oxidative stress; 3) inflammatory
cytokines; 4) increased catabolic state, through hypotha-
lamo-pituitary axis; 5) muscle insulin resistance;
6) abnormal muscle progenitor cells differentiation to an
adipocyte-like phenotype as a result of paracrine signals
from (adipo)cytokines.
Adipose tissue is classified as white adipose tissue
(WAT), the major energy storing tissue, brown adipose
tissue (BAT), which mediates non-shivering thermogen-
esis and brite adipocytes (brown in white). Increasing
BAT and energy expenditure in adult humans could be
a therapeutic strategy to combat obesity. Brown adipo-
cytes are thought to originate from a precursor shared
with skeletal muscle that expresses Myf5-Cre, while
white adipocytes originate from a Myf5-negative precur-
sors. This provides a rational explanation to why BAT is
more metabolically favorable than WAT, even if the
situation is more complex because subsets of white adi-
pocytes also arise from Myf5-Cre expressing precursors.
Differences in origin between adipocytes could explain
metabolic heterogeneity between depots and/or influ-
ence body fat patterning particularly in lipodystrophic
disorders.
Irisin is a newly discovered myokine, associated with
‘browning’ of the WAT. It displays a day-night rhythm,
is correlated with lean body mass, and increases after
exercise in healthy young individuals, despite an associa-
tion with major adverse cardiovascular events and
polycystic ovary disease [1]. Deficiency of myostatin, and
thus stimulation of muscle growth, has also been
reported to induce irisin and its precursor FNDC5
expression in muscle and drive the browning of WAT
in mice.
Familial partial lipodystrophy, Dunnigan variety
(FPLD2), an autosomal dominant disorder caused by
LMNA mutations, is characterized by fat loss from the
extremities and apparent muscular hypertrophy. How-
ever, it is unclear whether these patients appear muscu-
lar because of a lack of subcutaneous fat or have an
actual increase in muscle mass [2]. Moreover adipose
tissue mitochondrial dysfunction triggers a lipody-
strophic syndrome with insulin resistance, hepatosteato-
sis, and cardiovascular complications [3,4].
Therefore, our objective was to identify the status of
lean mass in LMNA-mutated lipodystrophic syndromes
and to determine simple biomarkers to differentiate
LMNA-mutated and acquired lipodystrophies. To do so,
we assessed the lean (as a surrogate of muscle mass)
and fat mass with absorptiometry in FPLD2 patients,
non-diabetic obese and control subjects using dual-
emission x-ray absorptiometry and magnetic resonance
imaging, and measured the myokine irisin and the adi-
pokine leptin blood levels . Our hypothesis is that the
rupture of balance between physiological lean and fat
mass in lipodystrophic syndromes could explain the evo-
lution towards insulin-resistance (Trial registration: Clin.
gov2009-AO-1169-48/PHRC2009 09/094).
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